All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Olverembatinib Delivers Durable Responses in T315I-Mutant, TKI-Resistant CML, Ph+ ALL

December 23rd 2022

Olverembatinib demonstrated sustained efficacy and reduced toxicity with longer follow-up in patients with TKI-resistant, T315I-mutant chronic myeloid leukemia in chronic phase and accelerated phase.

Doublet Combinations Could Shift Frontline Treatment Paradigm in High-Risk MDS

December 23rd 2022

Guillermo Garcia-Manero, MD, discusses the exploration of these doublet therapies and what they could mean for the high-risk myelodysplastic syndromes treatment landscape, the difficulties in making strides for patients with relapsed/refractory disease, and the top highlights in myelodysplastic syndromes from the 2022 ASH Annual Meeting.

Efficacy of Trastuzumab Deruxtecan Highlights the Need for Consistent HER2 Testing Practices in Metastatic Breast Cancer

December 23rd 2022

Michelle Shiller, DO, AP/CP, MGP, discusses the evolving role of HER2 as a biomarker for the treatment of patients with breast cancer and the impact of findings from the DESTINY-Breast02, DESTINY-Breast03, and DESTINY-Breast04 trials on the HER2 testing landscape.

Florida Cancer Specialists & Research Institute Supports American Cancer Society Guidelines for Colonoscopies

December 23rd 2022

Florida Cancer Specialists & Research Institute, LLC takes exception to a recent study published in the New England Journal of Medicine suggesting that colonoscopies are not as effective at preventing colorectal cancer deaths as previously thought.

Emergence of Tebentafusp Underscores the Need for Additional Advancements in Uveal Melanoma

December 23rd 2022

Richard D. Carvajal, MD, discusses the implications of the FDA approval of tebentafusp in uveal melanoma, the possibility of exploring tebentafusp in other HLA subtypes, and other areas of intriguing research in uveal melanoma.

Japan Approves Second-line Axi-cel for LBCL

December 23rd 2022

Japan’s Ministry of Health, Labor and Welfare has approved axicabtagene ciloleucel for the initial treatment of patients with relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

Lisaftoclax With or Without Rituximab or Acalabrutinib Elicits Favorable Responses and Safety in CLL/SLL

December 23rd 2022

Lisaftoclax alone or in combination with acalabrutinib or rituximab was active across a range of doses and displayed a tolerable safety profile in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

December 23rd 2022

The FDA has approved mosunetuzumab-axgb (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

Frontline Domvanalimab Plus Zimberelimab Improves Responses in PD-L1–High Metastatic NSCLC

December 22nd 2022

The combination of domvanalimab plus zimberelimab with or without etrumadenant generated an improvement in overall response rate and progression-free survival compared with zimberelimab alone in patients with PD-L1–high metastatic non–small cell lung cancer, according to findings from the phase 2 ARC-7 trial.

In-House Next-Generation Sequencing Improves Turnaround Time in NSCLC

December 22nd 2022

Lauren Ritterhouse, MD, PhD, discusses next-generation sequencing testing platforms and the importance of establishing processes for tissue collection in non–small cell lung cancer.

Adagrasib Provides New Option for Patients with KRAS G12C–Mutant NSCLC

December 22nd 2022

The FDA’s accelerated approval of adagrasib for adult patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer who have received at least 1 prior systemic therapy has provided a second KRAS G12C inhibitor option for patients.

Evolution of Targeted Therapy Improves Clinical Benefit in Blood and Bone Marrow Cancers

December 22nd 2022

Edward J. Pearson, MD, and colleagues, discuss the expanded role of targeted therapies in the treatment of patients with hematologic malignancies.

Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists

December 22nd 2022

As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.

FDA Grants Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

December 22nd 2022

The FDA has granted a breakthrough therapy designation to adagrasib plus cetuximab in patients with KRAS G12C–mutated, advanced colorectal cancer whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.

Melanoma Expert Focuses on Finding the Next Best Therapy

December 22nd 2022

Clinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.

Review of Curative Treatment Strategies for HCC

December 22nd 2022

The panel shares insight as to which patients might be candidates for curative therapies such as embolization techniques and liver transplant.

Radiation Therapy Plus Surgery May Improve Local Control in Localized Pelvic Ewing Sarcoma

December 22nd 2022

R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.

Overview of Hepatocellular Carcinoma Risk Factors

December 22nd 2022

Ghassan Abou-Alfa, MD leads Robert Lewandowski, MD, FSIR, and Amit Singal, MD in a discussion of the main risk factors for hepatocellular carcinoma.

Lenalidomide/Rituximab Regimens Show Encouraging Responses in Relapsed/Refractory Follicular Lymphoma, But Slow Accrual Axes Study

December 21st 2022

The regimen of lenalidomide in combination with rituximab with bendamustine are effective therapies for relapsed/refractory follicular lymphoma, with high rates of overall and complete metabolic response by PET, according to data from the randomized phase 2 HOVON110/Rebel trial.

Fluorouracil Is Inappropriate for Optimal Adjuvant Chemotherapy in High-Risk Early Breast Cancer

December 21st 2022

Updated results from the phase 3 GIM 2 study confirm previous findings showing that fluorouracil should not be a part of adjuvant chemotherapy for patients with high-risk early breast cancer.